ºÚÁÏÍø

ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 2975

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Investigating miRNA-661 and ATG4b mRNA expression as a potential biomarkers for hepatocellular carcinoma

12th International Conference on Pediatric Pathology & Laboratory Medicine

Osama Saber, Mahmoud A Ali, Marwa Matboli, Nashwa El-Khazragy, Nourhan Hossam, Ahmed Hamdy, Sarah El-Nakeep, Ayman El-Sayed Shafei1 and Randa Mostafa

Armed Forces College of Medicine, Egypt Ain Shams University, Egypt

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI:

Abstract
Aim: We aimed to examine the statistical association of serum expression of miR-661 and ATG-4b mRNA with HCC based on in silico data analysis followed by clinical validation. Patients & Method: Bioinformatics prediction was first applied to retrieve the potential miR serving as an epigenetic regulator of ATG-4b mRNA. Real-time quantitative polymerase chain reaction (RT-qPCR) were used to examine the expression of miR-661 and candidate target gene ATG-4b mRNA in 105 hepatocellular carcinoma (HCC) patients, 50 chronic hepatitis C infection (CHC) patients and 45 healthy controls. The prognostic efficacy of the chosen genes was also explored. Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14% and 77.14%, respectively, HCC patients with strong discriminating power between HCC and control (AUC=0.9 and 0.8, respectively). The median follow up period was 28 months. The survival analysis showed that both ATG-4b mRNA and miR-661 were independent prognostic factors. Of note, we found that miR- 661 was positively correlated with ATG-4b mRNA in patients� sera samples. Conclusion: This is the first report about the considerable clinical use of miR-661 and ATG-4b mRNA in early detection and follows up of HCC patients.
Biography

Email: habiba20062001@yahoo.com

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top